You are hereFebruary 26, 2018
What’s the Stem Cells Buzz this Week? - AR and Wnt Signaling in the Prostate, Stem Cell Therapies for Brain Cancer, ASC-Containing Hydrogels, Cardiac Cell Therapy!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Roles of AR in Prostatic Development and Regeneration
A new study from the lab of Zijie Sun (Stanford University School of Medicine, CA, USA) recently set forth to discover how the androgen and Wnt signaling pathways regulate prostate development, maturation, and regeneration. Towards this aim, He et al. developed new model mice and established an indispensable role for the androgen receptor (AR) in Wnt-responsive cells during prostate development, morphogenesis, and regeneration. See STEM CELLS now for all the additional details.
Autologous Stem cell Therapies for Brain Tumors
An exciting new study from Khalid Shah (Harvard Medical School, MA, USA) has recently explored the potential for engineered neural stem cells (NSCs) derived from induced pluripotent stem cells (iPSCs) for the treatment of brain cancer. Bhere et al. established that NSCs engineered to express tumor-specific death-receptor ligand and suicide-inducing proteins display anti-tumor activity after synthetic-extracellular-matrix encapsulation and transplantation into a mouse model of brain cancer. For more detail on this fantastic study, see STEM CELLS now!
ASC-Containing Hydrogels as Adjuncts to Autografts
A new study from the lab of Robert J. Christy (United States Army Institute of Surgical Research, JBSA Fort Sam Houston, Texas, USA) sought to study the potential for adipose-derived stem cells (ASCs) in the treatment of burn wounds. Burmeister et al. assessed feasibility and efficacy of in situ ASC delivery via PEGylated fibrin (FPEG) hydrogels as adjuncts to meshed split-thickness skin grafts in a porcine model. Excitingly, the results demonstrate that FPEG acts as both scaffolding to prevent contraction and as a delivery vehicle for ASCs to accelerate angiogenesis. For more details regarding this encouraging new strategy, head over to STEM CELLS Translational Medicine now!
New Future Directions for Cardiac Cell Therapy
Both direct and indirect mechanisms mediate tissue regeneration by stem cell therapy, although several limitations currently hamper clinical application. Now, a concise review from the lab of Ke Cheng (University of North Carolina at Chapel Hill and North Carolina State University, USA) introduces current barriers and limitations associated with stem cell therapies for ischemic heart disease treatment. These include low retention rate, tumor growth risks, off-target migration, and short-life in storage. Furthermore, Tang et al. provide potential solutions by summarizing the latest technological developments employed to improve cell retention, reduce transplantation risk, and target cells to the injury. See STEM CELLS Translational Medicine now for a great read!
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!